Related Experiment Videos
[High dose chemotherapy of solid tumors]
K Höffken1, R Kath, H J Fricke
1Klinik und Poliklinik für Innere Medizin II (Onkologie, Hämatologie, Endokrinologie, Stoffwechselerkrankungen). Friedrich-Schiller-Universität Jena.
Medizinische Klinik (Munich, Germany : 1983)
|July 15, 1997
Summary
High-dose chemotherapy (HDT) with autologous peripheral blood stem cell (PBSC) retransfusion is effective for advanced solid tumors. While managing myelosuppression, non-hematological toxicity remains a dose-escalation challenge.
Area of Science:
- Oncology
- Hematology
- Stem Cell Transplantation
Context:
- High-dose chemotherapy (HDT) utilizes hemopoietic growth factors and autologous peripheral blood stem cell (PBSC) retransfusion for advanced solid tumors.
- PBSC retransfusion effectively manages myelosuppression, but non-hematological toxicity limits further dose escalation.
Purpose:
- To review the efficacy and feasibility of HDT with PBSC retransfusion in treating various advanced solid tumors.
- To highlight the role of HDT in current and future cancer treatment strategies.
Summary:
- HDT followed by autologous PBSC retransfusion has demonstrated feasibility and efficacy across multiple solid tumor types, including breast, testicular, ovarian, small cell lung cancer, melanoma, glioblastoma, and soft-tissue sarcoma.
- The procedure involves initial dose-intense chemotherapy to assess chemosensitivity and mobilize stem cells, which are then collected via apheresis.
- Autologous bone marrow transplantation has been largely superseded by PBSC retransfusion with growth factor support.
Impact:
- HDT with PBSC retransfusion offers a viable treatment option for advanced solid tumors, showing tolerable toxicity.
- This approach is expected to gain importance in primary solid tumor treatment strategies in the near future.